Evidence map›Paper›PMID 38920311›Full record

ArticleThe oncologist2024

High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer.

Lilian van Wagensveld, Tom Van Nyen, Daniela Annibali, Gabe S Sonke, Roy F P M Kruitwagen, Frederic Amant, Hugo M Horlings

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lilian van WagensveldDepartment of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands.
Tom Van NyenGynecological Oncology Laboratory, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000 Leuven, Belgium.
Daniela AnnibaliGynecological Oncology Laboratory, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000 Leuven, Belgium.
Gabe S SonkeDepartment of Medical Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Roy F P M KruitwagenGROW, School for Oncology and Reproduction, 6229 HX Maastricht, The Netherlands.
Frederic AmantGynecological Oncology Laboratory, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000 Leuven, Belgium.
Hugo M HorlingsDepartment of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

Funding

Dutch Cancer Society IKNL2014-6838Kom Op Tegen Kanker-The Flemish Cancer Society 3M150511
6 · The paper itself

Abstract

introductionHigh-grade serous ovarian cancer (HGSOC) is characterized by high mortality and prevalent recurrences. This study investigates the prognostic value of phosphoglycerate dehydrogenase (PHGDH) in HGSOC which has been linked to metabolic reprogramming and recurrences in other cancers.

methodsData from 306 patients with advanced-stage HGSOC treated between 2008 and 2015 were analyzed. PHGDH expression levels were determined using immunohistochemistry and categorized as "low" or "high."

resultsPHGDH-high was associated with higher FIGO stage and increased use of neoadjuvant chemotherapy. Patients with PHGDH-high tumors had significantly worse survival than PHDH-low, even after adjusting for confounding factors.

Indexed as

Cystadenocarcinoma, SerousOvarian NeoplasmsPhosphoglycerate DehydrogenaseAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMiddle AgedNeoplasm GradingPrognosisBiomarkers, TumorPhosphoglycerate Dehydrogenasecarcinomafemalehumansovarian epithelial/drug therapyovarian neoplasms/pathologyphosphoglycerate dehydrogenase/metabolism

Identifiers

PMID38920311
PMCPMC11379630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.